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CC BY-NC-ND license (http://creativeAbstract Cartilage defects are a challenge to treat clinically due to the avascular nature of
cartilage. Low immunogenicity and extensive proliferation and multidifferentiation potential
make fetal stem cells a promising source for regenerative medicine. In this study, we aimed
to determine whether fetal synovium-derived stem cells (FSDSCs) exhibited replicative senes-
cence and whether expansion on decellularized extracellular matrix (dECM) deposited by adult
SDSCs (AECM) promoted FSDSCs’ chondrogenic potential. FSDSCs from passage 2 and 9 were
compared for chondrogenic potential, using Alcian blue staining for sulfated glycosaminogly-
cans (GAGs), biochemical analysis for DNA and GAG amounts, and real-time PCR for chondro-
genic genes including ACAN and COL2A1. Passage 3 FSDSCs were expanded for one passage on
plastic flasks (PL), AECM, or dECM deposited by fetal SDSCs (FECM). During expansion, cell pro-
liferation was evaluated using flow cytometry for proliferation index, stem cell surface
markers, and resistance to hydrogen peroxide. During chondrogenic induction, expanded
FSDSCs were evaluated for tri-lineage differentiation capacity. We found that cell expansion
enhanced FSDSCs’ chondrogenic potential at least up to passage 9. Expansion on dECMs pro-
moted FSDSCs’ proliferative and survival capacity and adipogenic differentiation but not oste-
ogenic capacity. AECM-primed FSDSCs exhibited an enhanced chondrogenic potential.
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Articular cartilage possesses limited regenerative abilities
when insulted with injury or degenerative disease such as
osteoarthritis. Autologous chondrocyte implantation (ACI)
is an effective procedure in treating articular cartilage
defects1; however, there are inherent drawbacks of
autologous chondrocytes including limited availability and
donor site morbidity which challenge the efficacy of this
approach.2 Human adult stem cells isolated from various
tissues have been proposed as promising sources for
supplementing autologous chondrocytes.3 Among them,
the synovium-derived stem cell (SDSC) has been charac-
terized as a tissue-specific stem cell for chondro-
genesis.4,5 Though having attracted extensive interest
and achieved great success in the past few years, unfor-
tunately, the miniscule quantities of adult stem cells and
their dramatic loss of self-renewal abilities and accom-
panying cellular senescence during ex vivo expansion
have forced researchers to look for additional
alternatives.6
Fetal stem cells have been discovered in prenatal tis-
sues, such as umbilical cord blood or vein, amniotic fluid,
placenta, and Wharton’s jelly.7 Normally discarded as
medical waste, these perinatal tissue-derived fetal stem
cells seem useful clinically for autologous transplantation
for fetuses and newborns, in utero transplantation for ge-
netic disorders, and for banking in later stages of life. Fetal
stem cells have been applied in clinical transplantation for
different indications in various countries since they are less
contentious than embryonic stem cells (ESCs).8e11 More
promising, intrauterine transplantation of fetal mesen-
chymal stem cells (MSCs) has benefited severe osteogenesis
imperfecta.12 Moreover, accumulating evidence suggests
that human fetal MSCs from aborted fetuses possess supe-
rior proliferation capacity, better intrinsic homing and
engraftment, more robust differentiation potential, and
lower immunogenicity, as compared to MSCs from perinatal
and postnatal sources.13 Recent studies also showed that
human fetal MSCs maintained their karyotypic and epige-
netic stability after more than 100 population doublings
in vitro, making them even more stable than human
ESCs.14,15
In our earlier report,16 late stage (passage 9) fetal SDSCs
(FSDSCs) were characterized; the chondrogenic potential of
FSDSCs was compared after expansion on either conven-
tional plastic flasks (PL) or decellularized extracellular
matrix (dECM) deposited by FSDSCs. Our recent work17
investigated the replicative senescence of adult SDSCs
(ASDSCs) resulting from ex vivo expansion on PL and the
functional rescue of the chondrogenic potential of ASDSCs
via expansion on dECM deposited by ASDSCs (AECM) and
FSDSCs (FECM), particularly by FSDSCs. However, we did not
know whether FSDSCs had replicative senescence and
whether AECM had advantages over FECM and PL in priming
human FSDSCs in their inherent property e chondrogenic
potential. In this study, we hypothesized that, different
from ASDSCs, FSDSCs did not exhibit replicative senescence
and chondrogenic potential of FSDSCs could be boosted by
expansion on AECM.Materials and methods
dECM preparation
Human FSDSCs were obtained from ScienCell Research
Laboratories (Carlsbad, CA) and ASDSCs were obtained from
Asterand (North America Laboratories, Detroit, MI). Both
cell types were used to prepare dECMs, termed FECM and
AECM, respectively, as described previously.16e18 Briefly, PL
was precoated with 0.2% gelatin (SigmaeAldrich, St. Louis,
MO) at 37 C for 1 h and seeded with passage 3 SDSCs at
6000 cells per cm2. After cells reached 90% confluence,
250 mM of L-ascorbic acid phosphate (Wako Chemicals USA
Inc., Richmond, VA) was added for 10 days. The deposited
matrix was incubated with 0.5% Triton X-100 containing
20 mM ammonium hydroxide at 37 C for 5 min to remove
the cells; they were stored at 4 C in phosphate-buffered
saline (PBS) containing 100 U/mL penicillin, 100 mg/mL
streptomycin, and 0.25 mg/mL fungizone until use.
Cell expansion and morphology
PL expanded passage 3 FSDSCs (PL3) were plated at 3000
cells per cm2 on FECM, AECM, or PL for one passage with
growth medium containing alpha-minimum essential me-
dium (aMEM), 10% fetal bovine serum (FBS), 100 U/mL
penicillin, 100 mg/mL streptomycin, and 0.25 mg/mL fun-
gizone. Expanded FSDSCs were termed FE4, AE4, and PL4.
Cell number was counted in 175 cm2 flasks (n Z 6) using a
hemocytometer. To observe cell morphology, FE4, AE4, and
PL4 were fixed in 4% paraformaldehyde; the cell membrane
was labeled with Vybrant Dil Cell-labeling solution (Life
Technologies, Grand Island, NY) and mounted with Prolong
Gold antifade reagent with 40,6-diamidino-2-phenylindole
(DAPI) (Life Technologies). Both FECM and AECM were
immunolabeled using monoclonal antibody for type I
collagen (SigmaeAldrich) conjugated with fluorescein iso-
thiocyanate (FITC) and visualized with a Nikon TE2000-S
Eclipse inverted microscope (Melville, NY).
Evaluation of cell proliferation and apoptosis and
resistance to oxidative stress
Before cell expansion, PL3 cells were labeled with CellVue
Claret (SigmaeAldrich) at 2  106 M for 5 min according to
the manufacturer’s protocol. After 8 days, expanded cells
were collected and measured using a BD FACS Calibur flow
cytometer (dual laser) (BD Biosciences, San Jose, CA).
Twenty thousand events of each sample were collected
using CellQuest Pro software (BD Biosciences) and cell
proliferation index was analyzed by ModFit LT version 3.1
(Verity Software House, Topsham, ME).
Apoptosis of expanded cells was detected using Annexin
V-FITC Apoptosis Detection Kit (BioVision Inc., Milpitas,
CA). Briefly, 2  105 detached cells from each group (nZ 3)
were labeled with FITC conjugated annexin V and propi-
dium iodide for 15 min. Samples were measured using FACS
Calibur (BD Biosciences) and analyzed using the FCS Express
software package (De Novo Software, Los Angeles, CA).
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peroxide (H2O2) at 37
C for 1 h. To measure intracellular
reactive oxygen species (ROS), cells were incubated with
1 mM 20,70-dichlorodihydrofluorescein diacetate (H2DCFDA)
(Life Technologies) for 15 min. The plates were read on a
FlUOstar OPTIMA (BMG Labtech Inc., Cary, NC) with an
excitation wavelength of 485 nm and emission of 530 nm.
Samples were assayed in triplicate.
Evaluation of surface markers during FSDSC
expansion
The following primary antibodies were used to detect
expanded FSDSC surface immunophenotype profiles: CD29
(abcam, Cambridge, MA), CD90 (BD Pharmingen, San Jose,
CA), CD105 (BioLegend, San Diego, CA), the stage-specific
embryonic antigen 4 (SSEA4) (BioLegend), integrin b5 (Cell
Signaling, Danvers, MA), and isotype-matched IgGs (Beckman
Coulter, Fullerton, CA). The secondary antibody was goat
anti-mouse IgG (H þ L) R-phycoerythrin conjugated (Life
Technologies). Samples (nZ 3) of each2 105 expandedcells
were incubatedon ice in cold PBS containing 0.1%Chrom-Pure
Human IgG whole molecule (Jackson ImmunoResearch Labo-
ratories, West Grove, PA) and 1% NaN3 (SigmaeAldrich) for
30min.The cellswere then sequentially incubated in thedark
in the primary and secondary antibodies for 30 min. Fluores-
cence was analyzed by a FACS Calibur (BD Biosciences) using
FCS Express software package (De Novo Software).
Effect of evaluation of cell expansion on FSDSC
chondrogenic potential
Plastic expanded FSDSCs (3  105) from passage 2 and
passage 9 were centrifuged at 500 g for 5 min in a 15-mL
polypropylene tube to form a pellet. After overnight incu-
bation (day 0), the pellets were cultured in a serum-free
chondrogenic medium consisting of high-glucose Dulbec-
co’s modified Eagle’s medium (DMEM), 40 mg/mL proline,
100 nM dexamethasone, 100 U/mL penicillin, 100 mg/mL
streptomycin, 0.1 mM ascorbic acid-2-phosphate, and 1
ITS Premix (BD Biosciences) with the supplementation of
10 ng/mL transforming growth factor b3 (TGF-b3, Pepro-
Tech Inc., Rocky Hill, NJ) in a 5% O2 incubator as long as
14 days. Chondrogenic potential was evaluated using Alcian
blue (AB) staining for sulfated glycosaminoglycans (GAGs),
biochemical analysis for DNA and GAG amounts, and
TaqMan real-time polymerase chain reaction (PCR) for
aggrecan (ACAN ) and type II collagen (COL2A1).
Effect of evaluation of culture substrates on FSDSC
chondrogenic potential
Plastic expanded FSDSCs (3  105) from passage 3 were
centrifuged at 500 g for 5 min in a 15-mL polypropylene
tube to form a pellet. After overnight incubation (day 0),
the pellets were cultured in a serum-free chondrogenic
medium in a 5% O2 incubator as long as 21 days. The pellets
from day 10 were assessed using AB staining for sulfated
GAGs and immunohistochemical labeling (IHC) for type II
collagen and TaqMan real-time PCR for ACAN and COL2A1.
The pellets from day 21 were assessed using AB staining forsulfated GAGs and IHC labeling for type II collagen,
TaqMan real-time PCR for ACAN and COL2A1, biochemical
analysis for DNA and GAG amounts, and biomechanical
testing for pellet Stiffness and Young’s Modulus (YMOD).
Effect of evaluation of culture substrates on FSDSC
adipogenic and osteogenic potentials
For adipogenesis, expanded cells on varied substrates were
seeded at 10,000 cells/cm2 and cultured for 21 days in
adipogenic medium (growth medium supplemented with
1 mM dexamethasone, 0.5 mM isobutyl-1-methyxanthine,
200 mM indomethacin, and 10 mM insulin). The cultures
(n Z 3) were fixed in 4% paraformaldehyde and stained
with a 0.6% (w/v) Oil Red O (ORO) solution (60% iso-
propanol, 40% water) for 15 min. Intracellular lipid-filled
droplet-bound staining was photographed under a Nikon
TE300 phase-contrast microscope (Nikon, Tokyo, Japan).
Adipogenic marker genes [lipoprotein lipase (LPL) and
peroxisome proliferator-activated receptor gamma
(PPARG)] were quantified using TaqMan real-time PCR.
For osteogenesis, expanded cells (nZ 3) were seeded at
8000 cells/cm2 and cultured for 21 days in osteogenicmedium
(growthmedium supplementedwith 0.1mMdexamethasone,
10 mM b-glycerol phosphate, 50 mM ascorbate-2-phosphate,
and 0.01 mM 1,25-dihydroxyvitamin D3) were collected for
alkaline phosphatase (ALP) activity assay with a reagent kit
(SigmaeAldrich) bymeasuring the formation of p-nitrophenol
(p-NP) from p-nitrophenyl phosphate following the manu-
facturer’s instructions. p-NP was quantified based on the
spectrophotometric absorbance at 405 nm and enzymatic
activity was expressed as millimoles of p-NP/min/mg DNA.
For evaluation of calcium deposition, induced cells (n Z 3)
were fixed with 70% ice-cold ethanol for 1 h and then incu-
bated in 40 mM Alizarin Red S (ARS) at pH 4.2 for 20 min with
agitation. After rinsing, matrix mineral-bound staining was
photographed. Quantification of staining was performed by
incubating cells with a solution of 10% acetic acid and 20%
methanol for 15 min to extract the calcium-chelated ARS
stain. Samples were analyzed for absorption at 450 nm,which
was normalized to total DNA amount for standardization.
Histology and immunolabeling
Representative pellets (n Z 2) were fixed in 4% para-
formaldehyde at 4 C overnight, followed by dehydrating in
a gradient ethanol series, clearing with xylene, and
embedding in paraffin blocks. 5-mm sections were stained
with AB staining (counterstained with fast red) for sulfated
GAGs. For immunohistochemistry, the sections were
immunolabeled with a primary antibody against type II
collagen [II-II6B3, Developmental Studies Hybridoma Bank
(DSHB), Iowa City, IA], followed by the secondary antibody
of biotinylated horse anti-mouse IgG (Vector, Burlingame,
CA). Immunoactivity was detected using Vectastain ABC
reagent (Vector) with 3,30-diaminobenzidine as a substrate.
Biochemical analysis for DNA and GAG amount
Representative pellets (n Z 4) were digested at 60 C for
4 h with 125 mg/mL papain in PBE buffer (100 mM
340 J. Li et al.phosphate, 10 mM ethylenediaminetetraacetic acid, pH
6.5) containing 10 mM cysteine. To quantify cell density,
the amount of DNA in the papain digestion was measured
using the QuantiT PicoGreen dsDNA assay kit (Life
Technologies) with a CytoFluor Series 4000 (Applied Bio-
systems, Foster City, CA). GAG was measured using dime-
thylmethylene blue dye and a Spectronic BioMate 3
Spectrophotometer (Thermo Fisher Scientific, Waltham,
MA) with bovine chondroitin sulfate (SigmaeAldrich) as a
standard.
TaqMan real-time PCR
Total RNA was extracted from pellets (n Z 4) using an
RNase-free pestle in TRIzol (Life Technologies). Two mg
of mRNA were used for reverse transcriptase with the
High-Capacity cDNA Archive Kit (Applied Biosystems) at
37 C for 120 min. Chondrogenic marker genes [ACAN
(Assay ID AIQJAP5) and COL2A1 (Assay ID Hs00156568_m1)]
and adipogenic marker genes [LPL (Assay ID
Hs00173425_m1) and PPARG (Assay ID Hs01115513_m1)]
were customized by Applied Biosystems as part of their
Custom TaqMan Gene Expression Assays. Eukaryotic 18S
rRNA (Assay ID HS99999901_s1 ABI) was carried out as the
endogenous control gene. Real-time PCR was performed
with the iCycler iQ Multi Color RT-PCR Detection kit and
calculated by computer software (PerkineElmer, Well-
esley, MA). Relative transcript levels were calculated as
c Z 2DDCt, in which DDCt Z DE  DC, DE Z Ctexp 
Ct18s, and DC Z Ctct1  Ct18s.Day 0 Day 7 Day 14
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Fig. 1 Later passage FSDSCs exhibited an enhanced chondrogenic
induced in a pellet culture system for 14 days. The effect of pass
histology, including pellet size (mm) and Alcian blue staining for sul
of pellets with DNA ratio indicating cell viability and a ratio of GAG
chondrogenic marker gene expression (ACAN and COL2A1). Data
*p < 0.05 indicated a statistically significant difference.Biomechanical testing
Representative pellets (nZ 6) were placed into a reservoir
filled with PBS and loaded onto the custom miniature
stepper motor driven compression device. This device used
a 10 g load cell and a miniature differential variable
reluctance transducer (DVRT) for displacement readout. A
small preload of 0.0001 N was applied followed by a 10%
strain at 1 s duration. From the linear portion of the load
displacement curve, the Stiffness and YMOD were calcu-
lated for the spherical shaped pellet according to Rodriguez
and colleagues.19
Statistical analysis
A ManneWhitney U test and a linear model with contrast
analysis were used for pairwise comparison. All statistical
analyses were performed with SPSS 13.0 statistical software
(SPSS Inc., Chicago, IL). p values less than 0.05 were
considered statistically significant.
Results
Cell expansion enhanced FSDSCs’ chondrogenic
potential
To determine whether cell passaging on plastic flasks would
affect expanded cells’ chondrogenic potential, human
FSDSCs from passage 2 and passage 9 were evaluated afteray 7 Day 14
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potential. Passage 2 (P2) and P9 FSDSCs were chondrogenically
aging on FSDSC chondrogenic capacity was evaluated using (A)
fated GAGs, (B) biochemical analysis for DNA and GAG contents
to DNA indicating chondrogenic index, and (C) real-time PCR for
are shown as average  standard deviation (SD) for n Z 4.
Fetal stem cells’ chondrogenic priming 34114-day chondrogenic induction. The pellets from passage 9
cells were bigger in size with a shiny surface; AB staining
showed comparable intensity to those from passage 2 cells
(Fig. 1A). Biochemical analysis data showed that, despite a
higher DNA ratio (by day 0) in 14-day pellets than those
from passage 9 cells, the pellets from passage 2 cells
exhibited a lower amount of GAG per pellet and a lower
ratio of GAG to DNA at both day 7 and day 14 (Fig. 1B). Real-
time PCR data showed that, compared to a continuing in-
crease in passage 9 cells, both ACAN and COL2A1 increased
at day 7 but decreased at day 14 in passage 2 cells (Fig. 1C).
dECM expansion promoted FSDSCs’ proliferative
and survival capacity
To evaluate the proliferative effect exerted by AECM and
FECM expansion, human FSDSCs were seeded for one pas-
sage on three different substrates: PL, AECM, or FECM.
Cells grown on PL exhibited random organization and
spindle morphology (red color); in contrast, cells expanded
on dECMs were more elongated and well organized by lining
up with matrix fibers in which type I collagen was positivelyAnnexin V
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Fig. 2 dECM expanded FSDSCs exhibited an enhanced prolifer
expansion on FECM. (A) FSDSCs were expanded on three substrates
labeled with Vybrant Dil Cell labeling solution (red) and the nucle
nolabeled for type I collagen (green). (B) Cell number was counte
cytometry was used to measure the proliferation index of expanded
apoptotic cells after expansion on the three substrates. (E) Gener
uated. Relative fluorescence emitted by fluorescent dye 20,70-dic
means  standard deviation (SD) of the mean for n Z 3. *p < 0.05detected (initial color was green and merged color was
yellow) (Fig. 2A). Six-day-expansion on FECM yielded the
highest cell number followed by AECM with PL having the
lowest (Fig. 2B). This finding was supported by proliferation
index (PI) data, in which AECM expansion yielded a 1.8-fold
increase and FECM expansion yielded a 2.5-fold increase
compared with PL expansion (Fig. 2C).
Our flow cytometry data showed that expanded FSDSCs
from all groups exhibited a similar percentage of apoptotic
cells (Fig. 2D). To evaluate cell viability after expansion on
these substrates, 1 mM H2O2 was applied to measure ROS
scavenging capacities in expanded FSDSCs. Both FECM and
AECM expanded cells produced about half the ROS
compared to PL upon stimulus (Fig. 2E), indicating dECM
expanded FSDSCs had higher viability in a harsh
environment.
To evaluate the effect of dECM expansion on MSC surface
markers of FSDSCs, our flow cytometry data showed that in
both AECM and FECM expanded FSDSCs, CD29 and CD90
were down-regulated in median fluorescence intensity
(median) with CD105 down-regulated in both median and
percentage. Interestingly, SSEA4 was up-regulated in bothParent
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i were stained using DAPI (blue), the dECM fibers were immu-
d in 175 cm2 flasks (n Z 6) using a hemocytometer. (C) Flow
ASDSCs. (D) Flow cytometry was used to measure percentage of
ation of ROS following hydrogen peroxide incubation was eval-
hlorofluorescein diacetate was measured and is presented as
indicated a statistically significant difference.
342 J. Li et al.percentage and median while integrin b5 was up-regulated
only in median (Fig. 3).AECM primed FSDSCs exhibited an enhanced
chondrogenic potential
To determine the priming effects of dECM expansion on
FSDSCs’ chondrogenic potential, expanded cells were
chondrogenically induced for up to 21 days. At the early
stage, 10-day pellets from PL3, PL4, and FE4 were similar in
size while those from AE4 were slightly bigger; the pellets
from dECM expansion were intensely stained with Alcian
blue for sulfated GAGs and immunolabeled for type II
collagen compared to those from PL expansion (Fig. 4A).
Chondrogenic marker gene (ACAN and COL2A1) expression
further revealed that dECM expansion up-regulated chon-
drogenic genes with AE4 being the highest, followed by FE4
(Fig. 4B). Consistent with the above cell expansion data in
Fig. 1C, PL4 cells exhibited a higher level of ACAN and
COL2A1 than PL3 cells after 10-day chondrogenic induction
(Fig. 4B).
At the later stage, 21-day pellets were evaluated for
chondrogenic differentiation and functionality. Similar to
the data at day 10, the pellets from PL3, PL4, and FE4
groups were comparable in size; the pellets from dECM
expansion, particularly from AE4, were bigger and intensely
stained for sulfated GAGs and type II collagen (Fig. 5A). The
pellets from AE4 exhibited the highest level of chondro-
genic marker genes (ACAN and COL2A1) followed by those
from PL expansion (ACAN and COL2A1); pellets from the
FE4 group had the lowest level (ACAN and COL2A1)
(Fig. 5B). Our biochemistry data showed that, after chon-
drogenic induction, AECM expansion yielded higher cell
viability (DNA% by day 0) though it was not significantly
different; AECM expansion yielded the highest GAG amountFig. 3 Flow cytometry was used to measure both percentage a
SSEA4, and integrin b5 in human FSDSCs after one passage on threper pellet, followed by those from FECM expansion with PL
expansion having the least with a comparable ratio of GAG
to DNA among groups (Fig. 5C). Our functionality data
suggested that dECM expansion yielded FSDSC pellets with
comparable Stiffness and Young’s modulus with those from
PL expansion (Fig. 5D).
dECM expanded FSDSCs exhibited an enhanced
adipogenic potential rather than osteogenic
capacity
To determine the rejuvenation effect of dECM expansion on
FSDSC adipogenic and osteogenic potentials, expanded
cells were incubated in corresponding lineage induction
medium for 21 days. Our adipogenic induction data showed
that expanded FSDSCs from varied substrates all stained
positive for ORO (Fig. 6A); FE4 exhibited the highest levels
of LPL and PPARG mRNAs followed by AE4 (LPL); PL
expansion had the lowest levels (Fig. 6B). Our osteogenic
induction data showed that expanded FSDSCs from varied
substrates all stained positive for ARS (Fig. 6C) and ALP
(Fig. 6E). Quantitative assessment for relative ARS density
(Fig. 6D) and ALP activity (Fig. 6F) did not show a significant
difference between groups.
Discussion
To achieve successful cartilage repair, stem cells for
application in cartilage regeneration should be obtained
easily, non-invasively, and in sufficient quantities and
then transplanted safely and efficiently to a host.20 Fetal
stem cells are a promising source; however, there are
limited studies investigating the potential of these sour-
ces in cartilage regeneration. Our group was the first to
characterize FSDSCs through expression of MSC markersnd median of MSC surface markers (CD29, CD90, and CD105),
e substrates (PL, AECM, and FECM).
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Fig. 4 AECM promoted expanded FSDSCs’ early chondrogenic differentiation. PL expanded passage 3 FSDSCs (PL3) were grown on
PL, AECM, or FECM for one passage; the expanded cells were PL4, AE4, and FE4. The above four cells were chondrogenically
induced in a pellet culture system for 10 days. (A) Before histological staining, pellet size was measured with a scale bar in mm;
Alcian blue (AB) was used to stain sulfated GAGs and immunohistochemistry labeling (IHC) was used to detect type II collagen (Col
II). (B) Real-time PCR was used to evaluate chondrogenic marker gene expression (ACAN and COL2A1) in day 10 pellets. Data are
shown as average  standard deviation (SD) for n Z 4. *p < 0.05 indicated a statistically significant difference.
Fetal stem cells’ chondrogenic priming 343CD90, CD105, CD29, and SSEA4 and multi-lineage differ-
entiation potential.16 In this study, we found that FSDSCs
exhibited an enhanced chondrogenic potential during cell
expansion at least up to passage 9. Expansion on dECM
promoted FSDSCs’ ability in proliferation and resistance
to oxidative stress, particularly on FECM, while expansion
on AECM promoted FSDSCs’ ability in chondrogenic dif-
ferentiation. Interestingly, expansion on dECM also
enhanced FSDSCs’ ability in adipogenesis rather than
osteogenesis.
Our previous reports showed that adult stem cell
passaging on conventional plastic flasks could cause repli-
cative senescence, evidenced by a down-regulation of the
ratio of GAG to DNA (chondrogenic index), ACAN, and
COL2A1 in porcine SDSCs from passage 3 to 521 and in
human bone marrow stromal cells (BMSCs) from passage 5
to 8.22,23 To the best of our knowledge, for the first time,
the findings in this study indicated that replicative senes-
cence did not apply to fetal source SDSCs, which exhibited
an enhanced chondrogenic capacity after expansion frompassage 2 to 9. The discrepancy between fetal and adult
SDSCs also existed in their response to dECM. In a recently
published parallel study,17 despite a higher level of GAG
amount in each pellet from FSDSCs compared to ASDSCs
(38.89  2.59 mg versus 24.60  1.42 mg) after a 21-day
chondrogenic induction, FSDSC expansion on either AECM
(1.52-fold increase) or FECM (1.38-fold increase) yielded
pellets with a lower level of GAG amount per pellet than
those from ASDSC expansion (2.78- and 4.42-fold increase,
respectively). Consistent with a previous report that fetal
BMSCs expressed higher osteogenic genes and deposited a
higher level of calcium compared to adult BMSCs in nude
mice,24 this finding suggested that human FSDSCs exhibited
higher chondrogenic potential than human ASDSCs despite
more sensitivity of ASDSCs to chondrogenic priming from
dECM expansion. Interestingly, we found the most chon-
drogenic capacity was achieved for ASDSCs by expansion on
FECM and for FSDSCs by expansion on AECM, indicating that
the shortage of “stemness” signals in adult SDSCs could be
supplemented by fetal matrix while the shortage of
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Fig. 5 AECM promoted expanded FSDSCs’ later chondrogenic differentiation. PL expanded passage 3 FSDSCs (PL3) were
expanded on either PL, AECM, or FECM for one passage; the expanded cells were PL4, AE4, and FE4. The above four cells were
chondrogenically induced in a pellet culture system for 21 days. (A) Before histological staining, pellet size was measured with a
scale bar in mm; Alcian blue (AB) was used to stain sulfated GAGs and immunohistochemistry labeling (IHC) was used to detect type
II collagen (Col II). (B) Real-time PCR was used to evaluate chondrogenic marker gene expression (ACAN and COL2A1). (C)
Biochemical analysis was used for DNA and GAG contents of pellets; cell viability in chondrogenic medium was evaluated using DNA
ratio (DNA content at day 21 adjusted by that at day 0); a ratio of GAG to DNA indicated chondrogenic index. (D) Functionality of
chondrogenically differentiated pellets was evaluated using Stiffness and Young’s modulus. Data are shown as average  standard
deviation (SD) for n Z 4. *p < 0.05 indicated a statistically significant difference.
344 J. Li et al.“differentiation” signals in fetal SDSCs could be boosted by
adult matrix.
Decellularized ECM deposited by MSCs has been proven
an effective ex vivo expansion system for both stem
cells16,21e23,25e27 and primary cells.28e30 In this study, we
found that, despite the inherent proliferative potential
that FSDSCs possess, which might be associated with longer
telomeres and higher telomerase activity in fetal MSCs,24
expansion on both dECMs, especially on FECM, increased
cell yield and resistance to oxidative stress. Compared to
ASDSC expansion in a parallel study,17 passage 3 FSDSC
expansion exhibited a higher level of proliferation index
when grown on Plastic (12.6 versus 2.1), AECM (22.7 versus
4.5), or FECM (31.0 versus 5.4). Similar enhancement of
adult BMSC ex vivo expansion by fetal BMSC ECM was re-
ported by Ng and colleagues.31
Although initiation of chondrogenesis of both fetal and
adult MSCs was modulated by distinct signaling mecha-
nisms,32 the fate of MSCs is also affected by the sur-
rounding ECM.33 For instance, dECM expansion could
protect SDSCs from oxidative and senescent insults16,18;
interaction with ECM from young cells was sufficient to
restore aged, senescent cells to an apparently youthful
state through induction of both Ku and SIRT1.34 Our recent
parallel study indicated that FECM was better than AECMin promoting cell proliferation and preventing apoptosis,
which might be explained by the discrepancy in chemical
composition of these two matrices.17 Our proteomics data
showed that FECM had more fibrillin-2, tenascin C, and
clusterin than AECM.17 Despite being largely restricted to
developing fetal tissues,35 enhanced expression of
fibrillin-2 and tenascin C has been observed in adults with
fibroproliferative conditions, such as wound healing and
sclerosis.36e38 AECM had more biglycan, decorin, derma-
topontin, elastin, periostin, thrombospondin-1, and TGF-
b1 than FECM.17 Decorin and biglycan were reported to
reduce proliferation of pre-adipocytes, partly by induction
of apoptosis.39 Dermatopontin has been implicated in
chondrogenic differentiation.40,41 Notably, periostin and
TGF-b are involved in osteochondrogenesis.42
Thrombospondin-1 signaling through CD47 inhibits self-
renewal by regulating c-Myc and other stem cell tran-
scription factors.43 The above data showed that,
compared with the role of FECM during cell expansion,
AECM has more matrix components favoring cell differ-
entiation and apoptosis rather than cell proliferation.
In this study, we also found that dECM expansion
enhanced FSDSC adipogenic potential rather than osteo-
genic capacity. This finding is in line with our parallel
study,17 in which ASDSCs were compared for tri-lineage
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Fig 6 dECM pretreatment promoted expanded FSDSC adipogenesis rather than osteogenesis. After expansion on PL, AECM, or
FECM, FSDSCs were replated in either adipogenic or osteogenic induction medium. After a 21-day incubation in adipogenic medium,
adipogenesis was evaluated using Oil Red O staining (A) and quantitative adipogenic marker genes (LPL and PPARG) (B). After a 21-
day incubation in osteogenic medium, osteogenesis was evaluated using Alizarin Red S (ARS) staining (C) and quantitative extra-
cellular calcium assay (D) as well as alkaline phosphatase (ALP) staining (E) and quantitative activity assay (F). Data were shown as
average  SD for n Z 4. *p < 0.05 indicated a statistically significant difference.
Fetal stem cells’ chondrogenic priming 345differentiation capacities after expansion on FECM and
AECM. A possible explanation is that SDSCs are an adult
stem cell inherently favoring chondrogenic and adipogenic
differentiation rather than osteogenic differentiation.4,5
dECM expansion augmented the inherent differentiation
potential of a specific stem cell; for instance, dECM
deposited by SDSCs favored expanded SDSCs’ chondrogenic
capacity21 while dECM deposited by BMSCs benefited
expanded BMSCs’ endochondral bone formation.22
In conclusion, even though there is a history of fetal
stem cell transplantation since 1928 and hundreds of clin-
ical trials using various types of fetal transplants have been
performed worldwide,44 there are few studies investigating
fetal stem cells from synovial tissue for chondrogenic po-
tential. Different from adult stem cells with replicative
senescence, in this study, we found that passaging human
fetal SDSCs could yield enhanced chondrogenic capacity.
Our study also suggests that a mature microenvironment
can render fetal stem cells with lineage specific differen-
tiation. The knowledge from this study will contribute to
future cartilage regeneration and engineering using fetal
source SDSCs in the treatment of osteoarthritic cartilage
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